Collum into the 10 billion-dollar contrast agent market Hengrui, Yangzijiang a competition.

Pharmaceutical Network Monthly official website data show that Colum Pharmaceuticals' application for generic generic seroin injections was acceptedThe domestic market of luteol injections for contrast agents only Boleco Italy has been approved for import up to now Colum Pharmaceuticals and subsidiaries have a contrast agent product in the review and approvalFigure: Collum Pharmaceuticals' registration of the injection of artalcohol Source: Official-web editing for magnetic resonance () enhanced scanning for brain, spinal and peripheral tissue lesionsBecause the ethyl alcohol mainly shortens the relaxation time in the weighted image, the selective signal of the dealcohol to the tissue selectivity of its distributable region seisyls, such as the pituitary and meninges structure without any blood-brain barrier, the veins and low-flow vein regions, and the central nervous system lesions that change the permeability of the blood-brain barrierIt can also be used for general magnetic resonance examinations including examinations of the head, neck, liver, breast, musculoskeletal system and soft tissue lesionsFigure: China's public medical institutions terminal chemical contrast agent manufacturer pattern source: Minnet China public medical institutions terminal competition pattern Minet net data data in China's public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal contrast agent market size increased rapidly year by year, respectively, 、、、 annual sales climbed to 100 million yuanFrom the competitive situation of enterprises are Jiangsu Hengrui Pharmaceutical, General Electric, Yangzijiang Pharmaceutical Group, Bayer and Boleco market share is superiorTable: Colum Pharmaceuticals has been reviewing the application for the listing of contrast agents since the date Source: Minnet China Drug Review Database So far, Collum Pharmaceuticals and subsidiaries have declared a total of applications for the listing of an contrast agent product are genericThe diazepam dsodium injection is Bayer's original research products in China's public medical institutions terminal sales close to 100 million yuan At present only Zhengda Tianqing Pharmaceutical Group's class imitation approved no enterprise evaluation; iodypaol injection is the annual sales of more than 100 million yuan of products currently obtained domestic approval of the enterprise has Shanghai Shili Pharmaceutical and Nanjing Zhengda Tianqing Pharmaceutical class imitation in the new year, the month and approved the sameAttalcohol injection seis temporarily no domestic enterprises were approved only Collum Pharmaceuticals declared to market to win the first imitation of the probability is greaterSource: Official website, the internal database review data statistics as of the end of the year, if there is any error, please point